Detalhe da pesquisa
1.
Multidisciplinary Decision-Making-ITAlian Consensus After Two Years of Real Practice on the Management of Severe Uncontrolled CRSwNP by Biologics (ITACA Study).
Curr Allergy Asthma Rep
; 24(3): 143-154, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38472601
2.
"Patient remodeling" as a consequence of uncontrolled and prolonged OCS use in severe asthma: how biologic therapy can reverse a dangerous trend.
J Asthma
; 61(1): 72-75, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37615543
3.
Effectiveness of dupilumab versus endoscopic sinus surgery for the treatment of type-2 chronic rhinosinusitis with nasal polyps: a preliminary report.
Eur Arch Otorhinolaryngol
; 281(3): 1317-1324, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37910208
4.
High proportion of inflammatory CD62Llow eosinophils in blood and nasal polyps of severe asthma patients.
Clin Exp Allergy
; 53(1): 78-87, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35490414
5.
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.
Respir Res
; 24(1): 135, 2023 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37210543
6.
Blood CD62Llow inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab.
Allergy
; 78(12): 3154-3165, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37792721
7.
Primary antibody deficiencies represent an underestimated comorbidity in asthma patients: efficacy of immunoglobulin replacement therapy in asthma control.
J Asthma
; 60(6): 1227-1236, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36282045
8.
Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience.
J Asthma
; 60(1): 158-166, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35112934
9.
ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study.
Respir Res
; 23(1): 36, 2022 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35183167
10.
Hypersensitivity reactions to biologicals: An EAACI position paper.
Allergy
; 77(1): 39-54, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34157134
11.
Effectiveness of low-dose intravenous immunoglobulin therapy in minor primary antibody deficiencies: A 2-year real-life experience.
Clin Exp Immunol
; 205(3): 346-353, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34061980
12.
Biologicals in atopic disease in pregnancy: An EAACI position paper.
Allergy
; 76(1): 71-89, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32189356
13.
Asthma and Chronic Rhinosinusitis: How Similar Are They in Pathogenesis and Treatment Responses?
Int J Mol Sci
; 22(7)2021 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33805199
14.
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.
PLoS Med
; 17(10): e1003348, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33125391
15.
Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement.
Allergy
; 75(11): 2764-2774, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32500526
16.
Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies.
J Allergy Clin Immunol
; 144(2): 584-593.e7, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30910492
17.
Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI.
Eur J Immunol
; 48(12): 2005-2014, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30252930
18.
IL-10-Producing Infliximab-Specific T Cells Regulate the Antidrug T Cell Response in Exposed Patients.
J Immunol
; 199(4): 1283-1289, 2017 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28716826
19.
Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient.
Clin Mol Allergy
; 17: 5, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30911288
20.
Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS).
J Clin Immunol
; 38(5): 602-609, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29951948